Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Early-stage Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT05760612
What this trial is testing

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Who this might be right for
Early-stage Breast CancerHER2-positive Breast CancerAdjuvant Treatment After Trastuzumab+2 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Large-scale testing (Phase 3)Study completedNCT03493854
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 500
Post-approval studies (Phase 4)Not Yet RecruitingNCT07589699
What this trial is testing

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Who this might be right for
Breast CancerHER2-positive Breast CancerEarly-stage Breast Cancer+1 more
The First Affiliated Hospital with Nanjing Medical University 59
Large-scale testing (Phase 3)Study completedNCT00615602
What this trial is testing

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 489
Testing effectiveness (Phase 2)Active Not RecruitingNCT05558722
What this trial is testing

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer Stage II
Xijing Hospital 31
Testing effectiveness (Phase 2)Ended earlyNCT05744375
What this trial is testing

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Spanish Breast Cancer Research Group 2
Large-scale testing (Phase 3)UnknownNCT04665986
What this trial is testing

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 50
Large-scale testing (Phase 3)Study completedNCT02040935
What this trial is testing

SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

Who this might be right for
Breast Cancer
Hoffmann-La Roche 128
Not applicableLooking for participantsNCT06781281
What this trial is testing

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Who this might be right for
Breast Cancer Invasive
Henan Cancer Hospital 709
Large-scale testing (Phase 3)Study completedNCT02162667
What this trial is testing

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Carcinoma of Breast
Celltrion 562
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06733233
What this trial is testing

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Who this might be right for
Breast Cancer, Estrogen Receptor-PositiveHER2 Low Breast Cancer
Guangzhou Women and Children's Medical Center 23
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT06001762
What this trial is testing

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Who this might be right for
Breast CancerEarly-stage Breast CancerHigh Risk Breast Carcinoma
Dana-Farber Cancer Institute 90
Large-scale testing (Phase 3)Study completedNCT04109391
What this trial is testing

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast CancerBreast Cancer+3 more
Tanvex BioPharma USA, Inc. 338
Large-scale testing (Phase 3)Study completedNCT03588091
What this trial is testing

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 355
Testing effectiveness (Phase 2)Study completedNCT01172223
What this trial is testing

Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
Prof Dirk Elling 81
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07416253
What this trial is testing

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07136974
What this trial is testing

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

Who this might be right for
Breast CancerHER2 + Breast Cancer
Henan Cancer Hospital 280
Testing effectiveness (Phase 2)Ended earlyNCT04113863
What this trial is testing

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

Who this might be right for
Breast Neoplasm Female
Mario Negri Institute for Pharmacological Research 76
Testing effectiveness (Phase 2)Study completedNCT00796978
What this trial is testing

Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

Who this might be right for
Breast Cancer
Cynthia Owusu, MD 56
Next Page